Our Doctors

Dr. Ahmad brings expereince from Ireland, the United Kingdom, Australia, New Zealand and the USA. He held consultant cardiologist posts in Australia and New Zealand before moving back to the UAE.

Dr Ahmad grew up in Abu Dhabi and moved to Ireland to pursue his medical training at the prestigious Trinity College in Dublin. He finished his Cardiology Training through the Royal Australasian College of Physicians program training in World renowned Green Lane Hospital in Auckland.

Dr Ahmad undertook further post cardiology fellowship training in advanced Interventional Cardiology at the Manchester Heart Centre in the Uk. He returned to New Zealand where he worked as a Consultant Interventional Cardiologist in the Mid-Central Region of the North Island including Hamilton Hospital. Prior to moving back to the United Arab Emirates, Dr Ahmad held consultant interventional cardiologist posts in the Northern Territory of Australia where he led and developed a successful remote interventional program and was the solo Interventional cardiologist for a radius of 2500kms. He is proficient in advanced coronary intervention having performed and supervised over 6000 diagnostic angiograms and 3000 interventional cases.

Qualification

• Bachelors of Arts – Trinity College – Ireland B.A.;
• Bachelors of Medicine and Surgery – Trinity College – Ireland Mb. B.Ch. B.A.O. (DUBL);
• Master of Arts– Trinity College – Ireland Mb. B.Ch. B.A.O. (DUBL); M.A.
• Certified Cardiac Device Specialist – International Board of Heart Rhythm Specialists – Boston U.S.A. IBHRE CCDS;
• Postgraduate Certificate in Clinical Ultrasound and Echocardiography- University of Melbourne Australia; P.G.C.U.
• Cardiac CT Certified – The John’s Hopkins University – Baltimore U.S.A.
• Fellowship of the Royal Australasian College of Physicians – Cardiovascular Diseases F.R.A.C.P. (Australia/New Zealand)

Core competencies

• High Case operator – Over 6000 Coronary cases done to date. Average 700 Coronary Angiographies per annum/350 Coronary Interventional Cases.
• Full competence in Coronary Intervention including: Left Main stenting; High risk angioplasty; Intra-aortic Balloon pumps;
• Experience using LV support devices (Including Impella)
• Chronic Total Obstruction Intervention; OCT and IVUS.
• TAVR hands on experience
• Certified Cardiac Device Specialist – International Board of Heart Rhythm Examiners – U.S.A.
• Full Competence in Cardiac CT Coronary angioghraphy – John’s Hopkins Baltimore – U.S.A.
• Full competence in Adult Transthoracic Echocardiographyl;
• Transesophageal Echocardiography and Stress echocardiography (Including Dobutamine).

Journal Publications

Vasim Farooq, Patrick W. Serruys, Ahmad H.S. Mustafa, Mamas A. Mamas, Nadim Malik, Hafez A.Alhous, Magdi El-Omar, Cara Hendry, Durgesh N. Rana, David Shelton, Paul K. Wright, Nadira
Narine, Bernard Clarke, Bernard Keavney, Farzin Fath-Ordoubadi, Douglas G. Fraser: Forward
and back aspiration during ST-elevation myocardial infarction: a feasibility study.
EuroIntervention: journal of EuroPCR in collaboration with the Working Group on
Interventional Cardiology of the European Society of Cardiology 04/2016; 11(14):e1639-e1648.
DOI:10.4244/EIJV11I14A315

Imthiaz Manoly, Andrew Brazier, Ahmed Mustafa, Vasim Farooq, Ragheb IR Hasan, Douglas G Fraser: Recurrent balloon rupture during Transcatheter Aortic Valve Replacement (TAVR) – a challenge to the Hybrid team. Journal of Cardiothoracic Surgery 12/2015; 10(Suppl 1):A316.
DOI:10.1186/1749-8090-10-S1-A316

Ahmad Mustafa, Safa Daghem, Vasim Farooq, Farzin Fath-Ordoubadi, Bernard Clarke:
Neoatherosclerosis, plaque rupture and very late stent thrombosis of a first generation drug
eluting stent treated with aspiration thrombectomy and newer generation drug eluting stent
implantation. International journal of cardiology 09/2015; 201:648-649.
DOI:10.1016/j.ijcard.2014.12.118

Ahmad Mustafa, Vasim Farooq, Imthiaz Manoly, Ragheb Hassan, Douglas G Fraser: Recurrent Balloon Rupture During Transcatheter Aortic Valve Replacement (TAVR) – Implication for Access Site Choice. Heart, Lung and Circulation 05/2015; 24(11). DOI:10.1016/j.hlc.2015.04.177

Ahmad H S Mustafa, Eric Holroyd, Rob Butler, Doug Fraser, Magdi El-Omar, James Nolan, Mamas AMamas: Transradial Intervention in ST Elevation Myocardial Infarction. Current Cardiology Reports 05/2015; 17(5):585. DOI:10.1007/s11886-015-0585-9

E.W. Holroyd, A.H.S. Mustafa, C.W. Khoo, R. Butler, D.G. Fraser, J. Nolan, M.A. Mamas: Major
bleeding and adverse outcome following percutaneous coronary intervention.

M Alawami, A Mustafa, K Whyte, M Alkhater, Z Bhikoo, J Pemberton: Echocardiographic and
Electrocardiographic findings in Patients with Obesity Hypoventilation Syndrome. Internal
Medicine Journal 11/2014; 45(1). DOI:10.1111/imj.12620

A. Kerr, A. Mustafa, M. Sculley, E. Broadbent, S. Wells: Your Heart Forecast Tool Patient Evaluation: A Randomised Controlled Trial. Heart, Lung and Circulation 07/2013; 22(7):562.
DOI:10.1016/j.hlc.2013.04.036

C. Creffier, J. Voss, A. Mustafa, C. Jones, N. Lever: Atrial Fibrillation Ablation Anticoagulation Audit – Auckland City Hospital. Heart, Lung and Circulation 07/2013; 22(7):554.
DOI:10.1016/j.hlc.2013.04.018

M. Alawami, A. Mustafa, J. Pemberton: Echocardiographic and Electrocardiographic Findings in
Patients with Obesity Hypoventilation Syndrome. Heart, Lung and Circulation 07/2013;
22(7):549. DOI:10.1016/j.hlc.2013.04.006

A. Lin, A. Mustafa, M. Lee, G. Devlin, I. Ternouth, A. McLachlan, A. Kerr: How Well Does the GRACE Score Perform in a New Zealand Acute Coronary Syndrome Cohort?. Heart, Lung and
Circulation 12/2012; 21:S41. DOI:10.1016/j.hlc.2012.05.108

A. Lin, A. Mustafa, G. Devlin, M. Lee, A. McLachlan, A. Kerr: Do Acute Coronary Syndrome Patients Categorised at High Risk by GRACE Receive more Frequent and Earlier Coronary Angiography?. Heart, Lung and Circulation 12/2012; 21:S36. DOI:10.1016/j.hlc.2012.05.096

A.H.S. Mustafa, A. Lin, M. Lee, A. McLachlan, A.J. Kerr: Ethnicity and Revascularisation Following
Acute Coronary Syndromes: A Four-Year Cohort Study. Heart, Lung and Circulation 08/2012;
21(8):506. DOI:10.1016/j.hlc.2012.03.075

A.H.S. Mustafa, N. Wijesuriya, G.F. Porter, J. Tisch, C. Young, D. Boddington, S. Tie: Thrombolysis in STEMI: A Two-Year Clinical Experience in Tauranga Hospital. Heart, Lung and Circulation
08/2012; 21(8):505–506. DOI:10.1016/j.hlc.2012.03.074

A. Lin, A. Mustafa, M. Lee, G. Devlin, I. Ternouth, A. McLachlan, A.J. Kerr: How Well Does the Grace Score Perform in a New Zealand Acute Coronary Syndrome Cohort?. Heart, Lung and
Circulation 08/2012; 21(8):496. DOI:10.1016/j.hlc.2012.03.054

A. Lin, A. Mustafa, G. Devlin, M. Lee, A. McLachlan, A.J. Kerr: Do Acute Coronary Syndrome Patients Categorised at High Risk by Grace Receive More Frequent and Earlier Coronary Angiography?. Heart, Lung and Circulation 08/2012; 21(8):496. DOI:10.1016/j.hlc.2012.03.053

A. Mustafa, G. F. Porter: Tauranga Hospital Cardiac Catherterisation Audit. Heart, Lung and
Circulation 06/2011; 20(6):401-402. DOI:10.1016/j.hlc.2011.03.071

Clinical Research: Sub PI in the following clinical trials:

STABILITY Phase III cardiovascular outcomes study designed to evaluate the effects of chronic treatment with darapladib versus placebo, when added to the standard of care, on the incidence of major adverse cardiovascular events (MACE) in high-risk patients with chronic CHD.

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin
(Ezetimibe/Simvastatin) vs Simvastatin

ENGAGE AF-TIMI 48 phase III clinical study of edoxaban, a direct, specific, oral factor Xa inhibitor that is being investigated in two different dosing regimens given once-daily, to prevent the occurrence of strokes and systemic embolic events in patients with atrial fibrillation (AF).

Dal-OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent ACS.

ALECARDIO: Phase III clinical investigation for aleglitazar (PPAR coagonist) to reduce cardiovascular morbidity and mortality in high risk (ACS) patients with Type 2 diabetes mellitus
DAPT is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety and effectiveness of dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents. Similar analysis will be conducted in a smaller cohort of bare metal coronary stent – treated subjects

SOLID-TIMI 52: A clinical outcomes study of Darapladib versus placebo in subjects following acute coronary syndrome to compare the incidence of major adverse cardiovascular events

Global Leaders : The study objective is to determine in all-comers patients undergoing PCI under standardisedtreatment (including the BioMatrix family of drug-eluting stents and bivalirudin), whether treatment with 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy is superior with respect to the composite of all-cause mortality or non-fatal new Q-wave MI compared to treatment with 12 months of standard
dual anti platelet therapy (DAPT) followed by aspirin monotherapy.